RxDoctor Payments Data

Bahadir Baris, MD

Pulmonary Disease · Columbus, GANPI 1710942446

Payments from drug & device makers

$375in general payments, 2019–2025

Across 23 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$174
  • Boehringer Ingelheim$90
  • Insmed, Inc.$75
  • Merck$19
  • Inogen, Inc.$14
  • United Therapeutics Corporation$3

What the payments were for

  • Food & beverage$29879%
  • Education$7721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK15$174
Boehringer Ingelheim4$90
Insmed, Inc.1$75
Merck1$19
Inogen, Inc.1$14
United Therapeutics Corporation1$3

How this compares

$375 in reported general payments places this provider in the 15th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$192,222
Medicare patients
564
Services billed
2,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$238,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter230$214,959
Spiriva RespimatTiotropium Bromide111$83,843
Breo ElliptaFluticasone/Vilanterol77$46,348
NucalaMepolizumab12$44,266
Stiolto RespimatTiotropium Br/Olodaterol Hcl53$42,511
XolairOmalizumab13$36,009
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$26,894
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$25,182
SymbicortBudesonide/Formoterol Fumarate50$22,323
Albuterol Sulfate HfaAlbuterol Sulfate309$10,797
Combivent RespimatIpratropium/Albuterol Sulfate17$9,892
Wixela InhubFluticasone Propion/Salmeterol47$7,872
Fluticasone-SalmeterolFluticasone Propion/Salmeterol51$6,786
Ventolin HfaAlbuterol Sulfate40$2,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$90$374,712194 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta$174$332,467363 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →